CX-5461 inhibits RNA Pol I in blood cancers.
In a preclinical study, the investigational drug CX-5461, which blocks the protein RNA polymerase I, extended survival in mouse models of highly aggressive acute myeloid leukemia and multiple myeloma refractory to standard therapy.